(XNCR) Xencor, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(XNCR) Xencor, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Xencor, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Vudalimab Phase II in mCRPC and solid tumors
Vudalimab is in Phase II for metastatic castration-resistant prostate cancer and other solid tumors, so it sits among Xencor, Inc.'s more advanced oncology assets. Its broad tumor reach keeps it in the high-growth quadrant of the BCG Matrix, but Phase II still means clinical and regulatory risk remains high.
VIR-3434 Phase II in hepatitis B
VIR-3434 is in Phase II for chronic hepatitis B, a market with about 254 million people living with HBV worldwide and long-term treatment needs. That scale gives the asset real upside if efficacy holds, so it fits a Star-style profile in the BCG matrix: high-growth disease area plus a late-enough stage to matter.
Tidutamab Phase II in neuroendocrine tumors
Tidutamab is already in Phase II for neuroendocrine tumors, so it sits well ahead of Xencor, Inc.'s Phase I assets in clinical maturity. That makes it a stronger "Star" type asset in the BCG lens if data keep improving. It also targets a specialist oncology niche where even modest response gains can support meaningful value creation.
Obexelimab autoimmune program
Obexelimab is one of Xencor's key autoimmune bets and fits a market that is already over $100B globally, with repeat use and long treatment tails. If its Phase 3 path stays on track, it can move from pipeline risk to a high-value growth asset for Xencor.
- Large, durable autoimmune demand
- Phase 3 upside can re-rate value
- High reward, but clinical risk remains
AMG 509 Phase I prostate cancer
AMG 509 is a partnered prostate-cancer program in phase I/II, and prostate cancer remains a huge market: the American Cancer Society projected 313,780 U.S. cases in 2025, while GLOBOCAN 2022 counted about 1.47 million new cases worldwide. That scale, plus partner support, makes it a stronger growth bet for Xencor, Inc.
- Partnered asset lowers solo risk.
- Large incidence supports upside.
- Phase I readouts drive value.
Xencor’s Phase II Stars Could Re-Rating the Story
Vudalimab, VIR-3434, and tidutamab are Xencor, Inc.'s clearest Stars: each is in Phase II, aimed at large or growing disease pools, and still has meaningful upside if data hold.
Vudalimab targets metastatic castration-resistant prostate cancer and other solid tumors; VIR-3434 targets chronic hepatitis B, a 254 million-person global market; tidutamab targets neuroendocrine tumors.
These assets can drive re-rating, but they are still clinical-stage, so readout risk remains high.
| Asset | Stage | Why Star |
|---|---|---|
| Vudalimab | Phase II | Large oncology reach |
| VIR-3434 | Phase II | HBV scale |
| Tidutamab | Phase II | Niche growth upside |
What is included in the product
Detailed Word Document
Xencor, Inc. BCG Matrix maps its oncology and antibody assets by growth and market share to guide invest, hold, or divest decisions.
Editable Excel File
Clean Xencor, Inc. BCG Matrix view that quickly spots strengths, cash cows, and risks for faster decisions.
Reference Sources
Provides a credible source trail for Xencor, Inc. that strengthens trust, speeds diligence, and supports better decision-making.
Cash Cows
Ultomiris royalty stream
Ultomiris is approved for 2 core rare diseases, PNH and aHUS, so Xencor gets a royalty stream from a product with steady, low-churn demand. Rare-disease drugs like this need limited extra promotion once adopted, which keeps the royalty margin high. With PNH affecting about 1 to 2 people per million, the base is small but durable, making this one of Xencor's clearest cash cows.
Monjuvi royalty stream
Monjuvi, approved by the FDA in 2020 for relapsed or refractory diffuse large B-cell lymphoma, gives Xencor, Inc. a steady royalty stream tied to commercial sales. Because the drug is already marketed, it brings recurring cash with little new development spend. That makes it a classic Cash Cow: low growth, but dependable cash generation.
XmAb platform license fees
Xencor, Inc.'s XmAb platform is the core licensing engine behind partnered antibodies, so it fits the cash cow profile: mature IP, low launch burn, and steady partner fees. The company monetizes the platform through recurring collaboration revenue and royalties rather than big sales spend, which makes XmAb a capital-light asset. In BCG terms, this is stable cash generation, not a high-growth bet.
Partnered marketed antibody royalties
Xencor's partnered marketed antibody royalties fit Cash Cow logic: the products are already on market, so Xencor collects recurring royalties with little direct selling cost. In 2025, this royalty stream helped fund a heavy R&D model while Xencor still reported about $1.0 billion in cash and investments, which supports the value of this low-capex income source.
- Marketed assets, not early bets
- Recurring royalties, low spend
- Cash support for R&D
Caris Life Sciences licensing agreement
Xencor's Caris Life Sciences licensing agreement fits a Cash Cow because it can bring recurring royalty-like income with little commercial spend. That makes the economics steady and capital-light, which is exactly what you want in a low-growth BCG Cash Cow bucket.
- Recurring income, low operating cost
- No full sales force needed
- Steady cash, limited growth
Xencor’s Cash Cows: Royalties, Licensing, and a $1B Cushion
Xencor, Inc.'s cash cows are its marketed royalty assets and XmAb licensing base: they generate recurring cash with little selling spend. Ultomiris and Monjuvi support steady royalty inflows, while Xencor, Inc. ended 2025 with about $1.0 billion in cash and investments, showing the cash cushion behind these mature assets.
| Cash Cow | Why it fits | 2025 data |
|---|---|---|
| Ultomiris | Royalties from marketed rare-disease sales | PNH, aHUS |
| Monjuvi | Recurring royalty stream | FDA approved 2020 |
| XmAb platform | Capital-light partner fees | About $1.0B cash and investments |
Preview Before You Purchase
Xencor, Inc. Reference Sources
This Xencor, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo content or placeholders—just the full, ready-to-use report. It’s formatted for clear strategic review and immediate use.
Dogs
Sotrovimab SARS-CoV-2 antibody
Sotrovimab, built to neutralize SARS-CoV-2, fits Xencor, Inc. as a Dogs asset: COVID-19 antibody demand has collapsed from the 2021 peak of millions of doses, and the FDA revoked its U.S. EUA in 2024 after variant resistance cut use. With little 2025-2026 commercial runway, it is a low-growth, low-share legacy asset.
VIR-7832 COVID-19 program
VIR-7832 was studied for mild-to-moderate COVID-19, but the market has shrunk sharply since the pandemic peak. With most anti-SARS-CoV-2 antibody demand fading and earlier mAbs losing traction as variants shifted, VIR-7832 has weak growth and limited future pull, so it fits Dog territory in Xencor, Inc.'s BCG view.
VIR-2482 Phase 1/2 influenza A
VIR-2482 is still in Phase 1/2, so it remains a high-risk, early-stage influenza A asset. Influenza is a crowded field, with multiple antivirals and vaccines already entrenched, so building real share is hard. With weak differentiation so far, this fits a Dogs call in Xencor, Inc.'s BCG view: low share, low value, and limited near-term cash impact.
BMS-986414 plus BMS-986413 ACTIV-2 COVID-19
BMS-986414 plus BMS-986413 is tied to the NIH ACTIV-2 COVID-19 trial, but pandemic-era antiviral and antibody assets have seen demand fade fast as emergency use collapsed. For Xencor, Inc., that leaves low growth visibility and weak proof of durable market share, which fits a Dog in the BCG Matrix.
- NIH-led ACTIV-2 program, not a core franchise.
- COVID-19 market urgency has materially cooled.
- Commercial upside looks limited and uncertain.
- Dog profile: low growth, low share.
AIMab7195 IgE reduction program
AIMab7195 IgE reduction program at Xencor, Inc. fits a Dog in BCG terms: it targets a large allergy market, but the field is crowded and dominated by entrenched players like Sanofi and Regeneron’s Dupixent, which posted about $13.6 billion in 2025 sales. Without clear share or late-stage proof, the program looks like a low-share asset.
IgE is a proven allergy target.
Competition is intense and established.
No clear market leadership yet.
Low-share profile fits a Dog.
Xencor’s Dogs Lack Growth as COVID Demand Fades
Xencor, Inc.'s Dogs are legacy or weak-fit programs with little 2025-2026 growth visibility and low share. Sotrovimab and VIR-7832 lost COVID-19 demand after the FDA revoked sotrovimab's U.S. EUA in 2024, while VIR-2482 and BMS-986414/BMS-986413 remain early and uncertain. AIMab7195 faces a crowded allergy market versus Dupixent's about $13.6 billion 2025 sales.
| Asset | Dog signal |
|---|---|
| Sotrovimab | EUA revoked; demand collapsed |
| VIR-7832 | Weak COVID-19 runway |
| VIR-2482 | Early stage; low share |
| AIMab7195 | Faces Dupixent scale |
Question Marks
Plamotamab Phase I in non-Hodgkin lymphoma
Plamotamab is still in Phase I for non-Hodgkin lymphoma, so Xencor, Inc. is testing safety and early efficacy, not harvesting share yet. That makes it a classic Question Mark in the BCG Matrix: high growth potential, but no proven commercial position. Non-Hodgkin lymphoma remains a large market, with about 80,000 new U.S. cases a year, but Plamotamab has not yet converted that opportunity into sales.
XmAb306 Phase I in solid tumors
XmAb306 is a Phase I oncology asset for selected solid tumors, so it is still in the proof-of-concept stage. The solid tumor market is large and keeps expanding, but XmAb306 has no late-stage data or approved revenue yet. That mix of high market upside and low current maturity fits classic Question Mark territory for Xencor, Inc.
XmAb104 Phase I in solid tumors
XmAb104 is a Phase I solid-tumor asset, so it sits in the Question Marks bucket: the market is huge, but clinical proof is still thin. Global oncology drug sales were about $200 billion in 2024, which shows the prize if XmAb104 can show clear benefit. Until Xencor, Inc. proves safety, response rates, and a real edge versus other early cancer drugs, it stays a high-risk, high-upside bet.
XmAb841 Phase I in solid tumors
XmAb841 is still in Phase I for solid tumors, so it has no meaningful market share yet and no commercial revenue to support its base case. That makes it a classic Question Mark in Xencor, Inc.'s BCG Matrix: high upside if the data improve, but high risk and still early.
- Phase I only
- Solid tumors target
- High upside, low share
- No current revenue
XmAb819 renal cell carcinoma program
XmAb819 is Xencor, Inc.’s renal cell carcinoma asset, and it sits in the Question Mark bucket because the program is still early with no meaningful market share yet. RCC is a high-value oncology market, with first-line advanced RCC therapies already generating multibillion-dollar annual sales, so positive data could give XmAb819 real upside.
If XmAb819 shows strong response and safety data versus current IO/TKI standards, it could move toward Star status; if not, it may stay a low-share bet. The key watch item is clinical proof, not current revenue.
- Early RCC program, no share yet
- Large oncology market, high upside
- Strong data could lift it to Star
Xencor’s Early Pipeline: High-Risk, High-Reward Question Marks
Xencor, Inc.’s Question Marks are all early-stage bets with no real share yet: Plamotamab in non-Hodgkin lymphoma, XmAb306 and XmAb104 in solid tumors, and XmAb841 and XmAb819 in solid tumors and RCC. The upside is big because non-Hodgkin lymphoma sees about 80,000 U.S. cases a year and oncology remains a massive market, but each program is still Phase I. They need clear safety and response data before they can move beyond high-risk, high-upside status.
| Asset | Stage | BCG read |
|---|---|---|
| Plamotamab | Phase I | Question Mark |
| XmAb306 | Phase I | Question Mark |
| XmAb104 | Phase I | Question Mark |
| XmAb841 | Phase I | Question Mark |
| XmAb819 | Early RCC | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.